LLY
NVO
Lilly is back with the receipts
Eli Lilly rolled out fresh analysis at the European Association for the Study of Diabetes meeting, and the headline is simple: its GLP-1 kingdom still looks pretty sturdy. In an indirect comparison, Zepbound came out ahead of Novo Nordisk’s Wegovy HD on weight loss in obese adults, while Foundayo also showed better results than oral semaglutide in type 2 diabetes.
The numbers are doing the heavy lifting
Using data from SURMOUNT-1 and STEP UP, Lilly says the 15 mg Zepbound dose produced 4.5% more weight loss than Wegovy HD at 72 weeks, while the 10 mg dose landed 3.2% ahead. The company also says the higher dose gave patients four times the odds of losing 20% or more of their body weight — the kind of stat that makes investors sit up and stop doomscrolling.
And this wasn’t just a one-note obesity story. Lilly’s Foundayo analysis, built from ACHIEVE-3 and PIONEER PLUS, showed 17.2 mg of the drug beat 25 mg oral semaglutide by 1.5% on weight loss and by 0.3% on A1C. Translation: Lilly wants you to know it’s not just winning the scale race, it’s also making a decent case that its diabetes portfolio can pull double duty.
Why Wall Street cares
These aren’t new approvals or a fresh earnings beat. They’re comparative clinical data, which is basically pharma’s version of a flex video. For Lilly, that flex supports the argument that Zepbound can keep taking market share in obesity, while Novo has to keep defending Wegovy’s relevance.
For investors, the big picture is that the obesity drug war is still very much on — and Lilly is trying to make it look less like a contest and more like a highlight reel.